Health
Anti-platelet drug class fails to extend survival in moderately ill COVID-19 patients – News-Medical.Net
A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or…
A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or lessen disease severity in patients with COVID-19 who were hospitalized but had a relatively moderate case, a new study finds. All…
Continue Reading
-
Noosa News20 hours agoWilliam Robinson dies aged 89
-
General20 hours agoCalls for corruption probe into completion of mayor’s Surfers Paradise Bowls Club site purchase
-
General20 hours agoMatt Wright wanted to hinder investigations into chopper crash ‘at almost any cost’, jury hears
-
Business22 hours agoTop brokers name 3 ASX shares to buy today 27 August 2025